首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis.
【24h】

Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis.

机译:肿瘤坏死因子相关的凋亡诱导配体对实验性类风湿关节炎关节炎症的减轻作用。

获取原文
获取原文并翻译 | 示例
           

摘要

This study focused on the potential therapeutic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on collagen-induced arthritis (CIA) and on the elucidation of the mechanisms involved. DBA/1J mice with established CIA were treated with various amount of recombinant soluble human TRAIL. The effects of TRAIL on the development and severity of CIA in this DBA/1J mouse model were assessed clinically and histologically, and a detailed investigation was conducted on proinflammatory cytokine and anticollagen-specific antibody levels. Cellular immunity was evaluated by investigating the proliferative responses and cytokine release profiles of splenocytes after TRAIL treatment. TRAIL treatment significantly reduced the severity and incidence of CIA, joint swelling, erythema, and edema. Histologic evaluations revealed that inflammatory cell infiltration, cartilage destruction, and bone erosion were significantly reduced in joints of TRAIL-treated mice with dose-dependent manner. TRAIL treatment also strongly decreased and/or normalized the productions of proinflammatory cytokines and of anti-collagen-specific antibodies in the sera of CIA mice. Furthermore, in vitro studies with primary splenocytes showed the cytotoxic effect of TRAIL on activated lymphocytes, with reduction of inflammatory cytokine release. These findings show that TRAIL administration is an effective anti-inflammatory treatment that prevents the development and progression of CIA in DBA/1J mice, and they suggest that TRAIL might be considered a potential treatment for human RA.
机译:这项研究的重点是肿瘤坏死因子相关的凋亡诱导配体(TRAIL)对胶原蛋白诱发的关节炎(CIA)的潜在治疗作用,并阐明了相关机制。用各种量的重组可溶性人TRAIL处理已建立CIA的DBA / 1J小鼠。在临床和组织学上评估了TRAIL对这种DBA / 1J小鼠模型中CIA的发展和严重程度的影响,并对促炎性细胞因子和抗胶原蛋白特异性抗体水平进行了详细研究。通过研究TRAIL处理后脾细胞的增殖反应和细胞因子释放曲线来评估细胞免疫。 TRAIL治疗可显着降低CIA,关节肿胀,红斑和水肿的严重程度和发生率。组织学评估显示,TRAIL治疗的小鼠关节中的炎症细胞浸润,软骨破坏和骨侵蚀以剂量依赖性方式显着降低。 TRAIL治疗还大大降低和/或使CIA小鼠血清中促炎性细胞因子和抗胶原蛋白特异性抗体的产生正常化。此外,对原代脾细胞的体外研究表明,TRAIL对活化的淋巴细胞具有细胞毒性作用,并减少了炎性细胞因子的释放。这些发现表明,TRAIL给药是一种有效的抗炎治疗,可防止CIA在DBA / 1J小鼠中发生和发展,并且表明TRAIL可能被认为是人类RA的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号